Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells

被引:1
|
作者
Ji, Bian-Sheng [2 ]
Li, Ming [2 ]
He, Ling [1 ]
机构
[1] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China
[2] Henan Univ Kaiferng, Key Lab Nat Med & Immune Engn, Nanjing, Peoples R China
来源
PHARMAZIE | 2010年 / 65卷 / 07期
关键词
MULTIDRUG-RESISTANCE; DRUG TRANSPORT; FUNCTIONAL RECONSTITUTION; MEMBRANE GLYCOPROTEIN; VINBLASTINE TRANSPORT; HYDROPHOBIC PEPTIDES; PURIFICATION; HYDROLYSIS;
D O I
10.1691/ph.2009.9803
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
P-Glycoprotein, a 170-180 kDa membrane glycoprotein that mediates multidrug resistance, hydrolyses ATP to efflux a broad spectrum of hydrophobic agents. To observe the interaction of a P-gp reversal agent with P-gp ATPase activity should provide further insights into the mechanisms of P-gp modulator. In this study, we analysed the effect of CJZ3, a lomerizine derivative, on the adenosine triphosphatase (ATPase) activity of human P-glycoprotein. The results showed that the basal P-gp ATPase activity was increased by CJZ3 with half-maximal activity concentration (Km) of 6.8 +/- 1.5 mu M, CJZ3 may interact with P-gp with a higher affinity and exhibit a more potent effect than verapamil (Ver). Kinetic analysis indicated a noncompetitive inhibition of Ver-stimulated P-gp ATPase activity and a competitive inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover, the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase activity showed a non-competitive and a competitive inhibition respectively. CJZ3 and CJX2 can bind P-gp either on overlapping sites or distinct but interacting sites, while CJZ3 and Ver as well as CsA can bind P-gp on separated sites in K562/DOX cells.
引用
收藏
页码:515 / 519
页数:5
相关论文
共 50 条
  • [41] CHARACTERIZATION OF THE ATPASE ACTIVITY OF THE MR 170,000 TO 180,000 MEMBRANE GLYCOPROTEIN (P-GLYCOPROTEIN) ASSOCIATED WITH MULTIDRUG RESISTANCE IN K562/ADM CELLS
    HAMADA, H
    TSURUO, T
    CANCER RESEARCH, 1988, 48 (17) : 4926 - 4932
  • [42] Doxorubicin-induced drug resistance is mediated by the p38 MAPK pathway in human leukemia K562 cells
    Chen, Yinghui
    Xu, Guoxiong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S44 - S44
  • [43] With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells
    Chen, Jie-Ru
    Jia, Xiu-Hong
    Wang, Hong
    Yi, Ying-Jie
    Li, You-Jie
    ONCOLOGY REPORTS, 2017, 37 (05) : 2735 - 2742
  • [44] Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway
    Wang, Hong
    Jia, Xiu-Hong
    Chen, Jie-Ru
    Wang, Jian-Yong
    Li, You-Jie
    ONCOLOGY REPORTS, 2016, 35 (06) : 3659 - 3668
  • [45] Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells
    Kairuki, Mutta
    Qiu, Qianqian
    Pan, Miaobo
    Li, Qifei
    Zhou, Jiaqi
    Ghaleb, Hesham
    Huang, Wenlong
    Qian, Hai
    Jiang, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (15) : 3347 - 3357
  • [46] Indirubin-3′-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells
    Lee, Ming-Yang
    Liu, Yi-Wen
    Chen, Ming-Ho
    Wu, Jin-Yi
    Ho, Hsing-Ying
    Wang, Qwa-Fun
    Chuang, Jing-Jing
    ONCOLOGY REPORTS, 2013, 29 (05) : 2072 - 2078
  • [47] Curcumin inducing apoptosis and inhibiting expression of p210bcr-abl protein in human chronic myelogenous leukemia K562 cells
    Xu, JH
    Chen, YZ
    Huang, XW
    Xie, JM
    Huang, ZQ
    FASEB JOURNAL, 2000, 14 (08): : A1516 - A1516
  • [48] MODULATION OF MULTIDRUG RESISTANCE P-GLYCOPROTEIN ACTIVITY BY ANTIEMETIC COMPOUNDS IN HUMAN DOXORUBICIN-RESISTANT SARCOMA CELLS (MES-SA/Dx-5): IMPLICATIONS ON CANCER THERAPY
    Angelini, A.
    Conti, P.
    Ciofani, G.
    Cuccurullo, F.
    Di Ilio, C.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2013, 27 (04): : 1029 - 1037
  • [49] Pentagalloyl Glucose-Targeted Inhibition of P-Glycoprotein and Re-Sensitization of Multidrug-Resistant Leukemic Cells (K562/ADR) to Doxorubicin: In Silico and Functional Studies
    Dechsupa, Nathupakorn
    Khamto, Nopawit
    Chawapun, Pornthip
    Siriphong, Sadanon
    Innuan, Phattarawadee
    Suwan, Authaphinya
    Luangsuep, Thitiworada
    Photilimthana, Nichakorn
    Maita, Witchayaporn
    Thanacharttanatchaya, Rossarin
    Sangthong, Padchanee
    Meepowpan, Puttinan
    Udomtanakunchai, Chatchanok
    Kantapan, Jiraporn
    PHARMACEUTICALS, 2023, 16 (09)
  • [50] Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells
    Kang, Qingwei
    Yan, Shu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (04) : 1345 - 1350